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Anaplastic large cell lymphoma (ALCL), an aggressive CD30-positive T-cell lymphoma,
comprises systemic anaplastic lymphoma kinase (ALK)-positive, and ALK-negative, primary
cutaneous and breast implant-associated ALCL. Prognosis of some ALCL subgroups is still
unsatisfactory, and already in second line effective treatment options are lacking. To identify
genes defining ALCL cell state and dependencies, we here characterize super-enhancer
regions by genome-wide H3K27ac ChIP-seq. In addition to known ALCL key regulators, the
AP-1-member BATF3 and IL-2 receptor (IL2R)-components are among the top hits. Specific
and high-level IL2R expression in ALCL correlates with BATF3 expression. Confirming a
regulatory link, IL-2R-expression decreases following BATF3 knockout, and BATF3 is recruited
to IL2R regulatory regions. Functionally, IL-2, IL-15 and Neo-2/15, a hyper-stable IL-2/IL-15
mimic, accelerate ALCL growth and activate STAT1, STAT5 and ERK1/2. In line, strong
IL-2Rα-expression in ALCL patients is linked to more aggressive clinical presentation. Finally,
an IL-2Rα-targeting antibody-drug conjugate efficiently kills ALCL cells in vitro and in vivo.
Our results highlight the importance of the BATF3/IL-2R-module for ALCL biology and
identify IL-2Rα-targeting as a promising treatment strategy for ALCL.
https://doi.org/10.1038/s41467-021-25379-9 OPEN
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Systemic anaplastic large cell lymphoma (ALCL) is anaggressive CD30-positive, mature T-cell non-Hodgkin lym-phoma (T-NHL), which can be divided into two entities
according to the presence or absence of Anaplastic Lymphoma
Kinase (ALK)-fusions, i.e., ALK-positive (ALK+) and ALK-negative
(ALK−) ALCL1,2. Furthermore, breast implant-associated ALK
−ALCL (BIA-ALCL) and primary cutaneous ALCL (pcALCL) are
acknowledged as (provisional) entities2, in particular the latter with
usually good prognosis3. Despite implementation of targeted
treatment strategies such as CD30 antibody-drug conjugates
(ADCs) into up-front treatment regimens4, the prognosis of some
particular systemic ALCL subtypes is unsatisfactory5, and there is
an unmet medical need for effective treatment options in the case of
relapsed and refractory disease6,7.
The AP-1 factors JUNB and BATF3, representing key com-
ponents of the ALCL cell-specific transcriptional program8–11,
interact with IRF412 and are essential for growth, survival and
TH17/ILC3-skewing of ALCL12,13. Remarkably, ALCL rarely
express T-cell receptor (TCR)β and TCR-associated signaling
molecules14–16, suggesting that other pathways substitute for
TCR-signaling. The maturation, proliferation and survival of
T cells critically depends on IL-217. IL-2 binds to IL-2 receptor
(IL-2R)αβγ with high, and to the heterodimeric IL-2Rβγ with
intermediate affinity18. IL-2R-expression has been linked to
ALCL19, and IL-2Rγ is epigenetically silenced in some ALCL,
ALK+ cell lines20. Whereas IL-2 is secreted by activated T-cells,
IL-15 together with its receptor IL-15Rα is usually membrane-
bound, and is presented to cells that express the IL-2Rβγ dimer.
Thus, the receptors of IL-2 and IL-15 use both the IL-2Rβ and
IL-2Rγ chains18.
Super-enhancers (SEs) are genomic regions bound by large
clusters of regulatory elements resulting in high-level gene expres-
sion of the respective genes, which are marked by extensive stret-
ches of histone 3 lysine 27 acetylation (H3K27ac)21,22 and help to
define unique tumor dependencies and therapeutically relevant
vulnerabilities23.
Here, we perform a SE analysis by genome-wide chromatin
immunoprecipitation sequencing (ChIP-seq) of H3K27ac in
ALCL cells in order to characterize in an unbiased manner the
transcriptional network and to identify key players that define
ALCL pathogenesis. We find BATF3 and IL2R components are
among the top SE hits, prompting us to analyze the link between
BATF3 and IL-2R components in ALCL cells, and to explore the
biological function of the IL-2/IL-2R system in ALCL in detail.
Results
Characterization of the super-enhancers in ALCL. To identify
in an unbiased manner cellular dependencies and vulnerabilities
which could ultimately be tools for ALCL therapy, we performed
genome-wide H3K27ac ChIP-seq for SE detection in 8 ALCL cell
lines (5 ALK+, 3 ALK−). By applying the ROSE algorithm22,24,
we defined SEs, characterized by extensive H3K27ac, in all 8 cell
lines (Fig. 1a, b and Supplementary Fig. 1a, b). These were
compared to published H3K27ac ChIP-seq datasets of CD3+,
CD8+ and CD4+ T-cell subsets from healthy donors as well as T-
cell-derived Jurkat cell line (Supplementary Fig. 1b).
Globally, we defined 538 and 722 SEs in Karpas-299 (systemic
ALCL, ALK+) and Mac-1 (derived from cutaneous T-NHL later
progressing to ALCL) cell lines (Fig. 1a, b), respectively. 225 genes
associated with SEs were shared between both cell lines (Fig. 1c
and Supplementary Table 1). The identified SEs were associated
with transcription factors and genes considered key pathogenic
factors in ALCL, including CD30, IRF4, JUNB, STAT1 and
STAT310,25,26. Furthermore, in the analyzed ALCL cell lines,
BATF312,27 was consistently found in a SE region with the highest
H3K27ac, as were the IL2RA and IL2RB loci (Fig. 1a, b and
Supplementary Fig. 1a, b). Remarkably, localization of BATF3
and IL2RA and/or IL2RB in SE regions was a common feature in
ALCL cell lines but not in primary T-cell controls or the Jurkat
cell line (Fig. 1a, b, c and Supplementary Fig. 1a, b), indicating an
ALCL-specific property.
To test whether the SE pattern seen in ALCL cell lines is
reflected in ALCL primary patient samples, we performed
H3K27ac analysis using the cut-and-run ChIP-seq technique on
2 primary patient samples (Fig. 1d and Supplementary Fig. 1c).
Overall, we found a similar SE pattern as in the ALCL cell lines.
In both patients #54 and #208, BATF3 and IL2RB were located in
SE regions, and IL2RA was located in SE region in patient #54.
Together, these data mirrored our findings in ALCL cell lines,
showing the presence of IL2R components and BATF3 in SE
regions in ALCL.
BATF3-regulated genes and pathways in ALCL. To identify
BATF3-regulated genes, RNA-seq of Karpas-299 cells after
CRISPR/Cas9-mediated BATF3 deletion was performed. Among
the most significantly downregulated genes in 3 different
CRISPR/Cas9-mediated BATF3-deleted clones was IL2RG (Sup-
plementary Fig. 2a), and IL-2- together with in ALCL well-
described IL-10- and STAT3-signaling was detected as being
deregulated25,28 (Fig. 1e and Supplementary Fig. 2b). In order to
distinguish direct from indirect BATF3-regulated genes, we per-
formed genome-wide BATF3 ChIP-seq in Karpas-299 cells. 354
of 581 (61%) downregulated genes after BATF3 CRISPR-
inactivation showed BATF3-binding in their regulatory regions,
indicating direct regulation by BATF3, whereas only 368 of 865
(43%) upregulated genes showed BATF3-binding peaks (Sup-
plementary Table 2). Remarkably, BATF3 occupied H3K27ac-
enriched SEs presenting at the IL2RA and IL2RB loci (Supple-
mentary Fig. 2c). Furthermore, binding of BATF3 at its own locus
suggests an autoregulatory loop, as often observed with SE
transcription factors (Supplementary Fig. 2d). Together, the SE
analyses and BATF3 target gene characterization suggested a
central role for BATF3 and IL-2/IL-2R signaling in ALCL.
Next, we explored publicly available RNA-seq data from 23
ALCL patients29 for genes positively correlated with BATF3
(Fig. 1f). Among 21,000 assigned and expressed genes, CD30 and
IL2RA were within the top 50 hits positively correlating with
BATF3 (both P < 0.001). Also, IL2RB positively correlated with
BATF3 expression (P= 0.027; Fig. 1f). The same pattern was
observed in an independent microarray dataset of 29 ALCL
patients30 (Supplementary Fig. 2e). In line, BATF3 and IL-2Rα
expression positively correlated (P= 0.0017) by immunohisto-
chemistry (IHC) of ALCL specimens using a tissue microarray
(TMA) (n= 63; Fig. 1g, Supplementary Fig. 2f and Supplemen-
tary Tables 3 and 4).
IL-2Rα/β/γ are highly expressed in ALCL but not other T-NHL.
To comprehensively examine expression of the IL-2R subunits,
IL-2Rα (also called CD25), IL-2Rβ (CD122) and IL-2Rγ (CD132),
in mature T-NHL, we performed immunostaining of TMA
comprising angioimmunoblastic T-cell lymphoma (AITL, n= 8),
peripheral T-cell lymphoma not otherwise specified (PTCL-NOS,
n= 23), ALCL with (n= 22) or without (n= 23) ALK-translo-
cation, and of non-neoplastic reactive lymph node controls
(n= 11) as well as of pcALCL specimens (n= 24). Strong positive
staining of all three IL-2R chains was seen in the majority of cases
of all ALCL subtypes, with the strongest expression in ALCL,
ALK+, whereas no comparable IL-2R expression was observed in
the other samples (Fig. 1h, Supplementary Fig. 3a and Supple-
mentary Tables 3 and 4). The BATF3 expression analysis showed
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a similar pattern (Supplementary Fig. 3b and Supplementary
Table 3), again suggesting a link between BATF3 and IL-2R
expression in ALCL. We subsequently tested IL2R and BATF3
expression in a broad cell line panel consisting of ALCL, ALK+,
ALCL, ALK−, BIA-ALCL31 and T-cell control cell lines. Again,
expression of IL2RA, IL2RB and BATF3 was restricted to ALCL
cell lines (Fig. 2a and Supplementary Fig. 3c, d, e).
BATF3 directly regulates IL-2Rα/β and CD30 in ALCL. To
assess if a direct link exists between BATF3 and IL-2R expression,
we examined the mRNA levels of IL2R in BATF3-knockout ALCL
cell lines. BATF3 deletion led to significantly reduced mRNA and
protein expression of all three IL-2R subunits in all tested ALCL
cell lines, and of IL-2Rα and IL-2Rγ in BIA-ALCL cells (Fig. 2b
and Supplementary Fig. 3f, g). Moreover, BATF3 deletion led to
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reduced growth in ALCL cell lines (Supplementary Fig. 3h).
Protein and pY-protein levels of STAT1, STAT5 and ERK1/2
were not consistently affected by CRISPR/Cas9-mediated BATF3
deletion (Supplementary Fig. 3i).
Both CD30 and BATF3 display specificity for ALCL11, and
JUNB is present on the AP-1 site within the CD30 promoter32,33.
Given our identification of SEs at CD30, BATF3 and IL2R loci,
and that CD30 and IL-2R are markers for activated lymphocytes,
we tested whether BATF3 also regulates CD30. CD30 expression
decreased following BATF3 deletion with a stronger effect in
ALCL, ALK+ cells (Fig. 2c), and BATF3 was recruited to CD30
regulatory regions as revealed by ChIP (Fig. 2d) and genome-
wide ChIP-seq (Fig. 2e). To independently assess AP-1 recruit-
ment to regulatory regions of IL2R members in ALCL, we
identified AP-1/TRE sites in the promoter or enhancer regions of
IL2R loci. The non-conserved 5’-TGAGTAA-3’ motif in the
IL2RA promoter and the conserved 5’-TGACTCA-3’ AP-1/TRE
site in the IL2RB enhancer showed strong ALCL-specific DNA-
binding (Fig. 2f and Supplementary Fig. 3j). Recruitment of
BATF3 to IL2RA and IL2RB regulatory regions was also observed
by ChIP in ALCL cell lines (Fig. 2g), confirming our BATF3
ChIP-seq in Karpas-299 and Mac-1 ALCL cells (Supplementary
Fig. 2c). Together, our data point towards a direct regulation of
IL2R and CD30 genes by BATF3/AP-1 in ALCL.
IL-2 could not be detected in tumor cells of 33 ALCL patients
nor in ALCL cell lines (Supplementary Fig. 4a, b and
Supplementary Table 3), suggesting other sources of IL-2 in
ALCL. Macrophages and plasma cells that do express IL-2 have
been described as being in proximity to ALCL cells34, which we
did also observe in a number of cases (Supplementary Fig. 4a).
Furthermore, elevated IL-2-levels were previously found in the
serum of a subgroup of ALCL patients but none was detected
upon remission or in B-NHL controls35. These data suggest that
IL-2 might be present at least in a subset of ALCL patients and to
act on the lymphoma cells.
IL-2/-15 promote ALCL growth and STAT1/5 and ERK sig-
naling. Thus, to functionally investigate IL-2/IL-2R signaling in
ALCL, we stimulated a panel of 7 ALCL cell lines with recombi-
nant human (rh) IL-2. With the exception of SUP-M2, lacking the
essential IL-2Rγ chain for IL-2 signaling, all ALCL cells showed
significantly increased metabolic activity reflecting cell growth
after rhIL-2 stimulation (Fig. 3a). Jurkat cells, lacking IL-2Rα and
IL-2Rβ, were used as an additional control and did not respond to
rhIL-2. Also, no growth stimulation of rhIL-2 was seen in ALCL
cell lines following BATF3 knockout (Fig. 3b). We also employed
Neo-2/15, an IL-2-mimic that binds to heterodimeric IL-2Rβγ and
is unrelated in amino acid sequence and topology to IL-236, which
showed the same growth-promoting effect as rhIL-2 in ALCL cells
with, but not without, BATF3 expression (Supplementary Fig. 4c,
d). Stimulation with these cytokines led to increased phosphor-
ylation levels of STAT1, STAT5 and ERK1/2, but not STAT3, in
ALCL cell lines except for SUP-M2 (IL-2Rγ-negative) and Jurkat
(IL-2Rα- and IL-2Rβ-negative; Fig. 3c and Supplementary Fig. 4e,
f). In limiting dilution assays on Karpas-299 and Mac-1 cells,
rhIL-2 supported cell growth at low cell densities (Fig. 3d). The IL-
2Rα-blocking antibody basiliximab attenuated rhIL-2-mediated
growth-promoting effect (Fig. 3e) and activation of STAT5 and
ERK1/2 (Supplementary Fig. 4g), confirming the specificity of
observed effects.
IL-2R family members IL-2Rβ and IL-2Rγ together with IL-
15Rα form the trimeric receptor complex for IL-1517,18. IL15RA
was expressed in all ALCL cell lines, whereas IL15 only in some
(Supplementary Fig. 5a, b). Positive IHC staining for IL-15Rα
(Supplementary Fig. 5c) and IL-15 (Fig. 3f and Supplementary
Table 5) was also seen in primary ALCL samples. Expression of
IL-15 and IL-15Rα together with high-level IL-2R suggests IL-
15R-complex formation. In line, rhIL-15 stimulation enhanced
cell growth in the majority of tested ALCL cell lines (Fig. 3g) via
activation of the same downstream targets as IL-2 signaling,
STAT1, STAT5 and ERK1/2 (Fig. 3h and Supplementary Fig. 5d,
e). These results further support the biological significance of
high-level IL-2R expression and interacting signaling components
for ALCL.
IL-2Rα level reflects clinical features of ALCL patients. We next
determined IL-2Rα expression in 88 pediatric ALCL, ALK+
patients of the NHL-Berlin-Frankfurt-Münster (BFM) study
group (German patients included in the ALCL99 trial37 or the
NHL-BFM trials38). Patients with high IL-2Rα expression of the
tumor (staining intensity (SI)= 3) had lower five-year overall
survival (OS) (Fig. 4a) compared to those with low expression
(SI= 0–2). Furthermore, we analyzed an independent cohort of
44 adult ALCL, ALK− patients from the French, Swiss and Czech
lymphoma study groups (Fig. 4b, Supplementary Fig. 6a and
Supplementary Table 6). Estimates for event-free survival (EFS)
and OS at 3 years for all 44 patients by IL-2Rα staining intensity
showed a possible difference in EFS, not reaching significance
(EFS 32% [95%-CI, 14–51%] for strong IL-2Rα positivity (SI= 3)
vs. 50% [95%-CI, 28–68%], P= 0.11) (Supplementary Fig. 6a).
First-line treatment for the patients was comparable in terms of
induction chemotherapy, but differed in consolidation strategy, as
10 of 44 patients received an autologous or allogeneic blood stem
cell transplantation (SCT) first-line (see Supplementary Table 6).
Therefore, we performed a subgroup analysis for patients not
receiving SCT as first-line consolidation. In this analysis, EFS was
significantly lower in patients with tumors showing strong
(SI= 3) IL-2Rα staining (24% [95%-CI, 7–45%] vs. 59% [95%-CI,
33–78%], P= 0.025) (Fig. 4b, left). A possible difference was
observed in OS (P= 0.056), not reaching significance (Fig. 4b,
right).
Targeting IL-2Rα induces ALCL death in vitro and in vivo.
Given the biological role of IL-2/IL-2R in ALCL, the recent
development of IL-2Rα-targeting strategies39,40, and the medical
Fig. 1 Genes encoding BATF3 and subunits of the IL-2R are highly acetylated at H3K27 and positively correlate. a Enhancers were ranked based on
increasing H3K27ac signals. Genes within SEs in Karpas-299 (ALK+) and Mac-1 (ALK−) ALCL cell lines are marked red. b H3K27ac ChIP-seq tracks at the
BATF3 locus with indicated SE regions. c Overlap of genes associated with SEs in Karpas-299 and Mac-1 cell lines. d Enhancers were ranked based on
increasing H3K27ac signals. Genes within SEs in primary ALCL patient samples (#54 and #208) are marked in red. e Identification of upstream regulators
among deregulated genes in CRISPR/Cas9-mediated BATF3-KO Karpas-299 cells by IPA 2020 analysis. f Analysis of BATF3-correlated genes in a
previously published RNA-seq dataset of 23 ALCL patients (BioProject PRJNA255877, SRA identifier SRP044708). Pearson correlation; P value based on
t-distribution. g Representative images of 63 patient samples measured of BATF3 and IL-2Rα IHC staining of ALCL, ALK+ in paired FFPE tissues sections.
h IHC quantification of IL-2Rα, IL-2Rβ and IL-2Rγ expression in mature T-NHL TMAs (reactive lymph node controls, n= 11; AITL, n= 8; PTCL-NOS, n= 23;
ALCL, ALK+, n= 22; ALCL, ALK−, n= 23) and pcALCL (n= 24) specimens. P values were determined by two-tailed unpaired Student’s t test. All box-
whisker plots represent the median (central line), 25th–75th percentile (bounds of the box) and minimum–maximum (whiskers).
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need for new treatment approaches for subgroups of ALCL, we
explored IL-2Rα as therapeutic target in ALCL. To this end, we
used ADCT-301 (camidanlumab tesirine), a recently developed
ADC composed of an IL-2Rα-targeting monoclonal antibody
coupled to a highly-potent pyrrolobenzodiazepine (PDB)-dimer
cytotoxic warhead39. Cells were treated with ADCT-301 or the
isotype control ADC B12-SG3249, recognizing HIV-gp120,
conjugated to the same linker-warhead as in ADCT-301. At doses
of 156 ng/ml and lower, ADCT-301 induced cell death of all
IL-2Rα-positive ALCL cell lines while it did not affect viability of
IL-2Rα-negative Jurkat and KE-37 cells (Fig. 4c). B12-SG3249 did
not affect cell viability. The LD50 of ADCT-301-induced cell
death was remarkably low (between 0.8 and 2.3 ng/ml) for ALCL
cell lines, but >156 ng/ml in the IL-2Rα-negative cell lines
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Fig. 2 BATF3 regulates expression of IL2R subunits and CD30 in ALCL. a IL2RA, IL2RB and IL2RGmRNA expression in cell line panel consisting of 13 ALCL
cell lines (6 ALCL, ALK+, 4 ALCL, ALK− and 3 BIA-ALCL), 4 T-cell leukemia-derived control cell lines (T) and PBMCs, or in b CRISPR/Cas9-mediated
BATF3-KO and CRISPR control ALCL cells, using quantitative RT-PCR. Data are indicated as means ± SD of biological triplicates. P values were determined
by two-tailed unpaired Student’s t test. c Cell surface expression of CD30 in BATF3-KO (red) or CRISPR control (green) ALCL cells, isotype control (gray)
and unstained cells (black). d BATF3 ChIP of the CD30 regulatory region as compared to a control region (Ref_Ch4). Combined data of two biological
replicates are shown as mean ± SEM (see Supplementary Table 8 for ChIP primer sequences). e ChIP-seq tracks at the CD30 locus for BATF3 and H3K27ac
in ALCL cell lines with indicated SE regions. f Electrophoretic mobility shift assay (EMSA) of AP-1 TRE complexes on the IL2RA promoter or IL2RB enhancer
region (see Supplementary Table 8 for probe sequences) in 10 ALCL cell lines and 4 T-cell leukemia-derived control cell lines. The positions of AP-1
complexes, nonspecific bands (n.s.) and free probes are indicated. Blots shown are representative of three independent experiments with similar results.
g BATF3 ChIP on IL2RA or IL2RB regulatory regions as compared to a control region (Ref_Ch4). Combined data of two biological replicates are shown as
mean ± SEM (see Supplementary Table 8 for ChIP primer sequences).
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(Fig. 4c), indicating the high efficacy and specificity of ADCT-301
for ALCL. Annexin V/propidium-iodide (PI) staining and
PARP1-cleavage (Supplementary Fig. 6b, c) in ADCT-301-treated
cells indicated induction of apoptotic cell death. When we tested
the effect of ADCT-301 or control ADC B12-SG3249 on STAT1
and STAT5 levels in ALCL cell lines, we found reduction of
pYSTAT5 in all tested cell lines and reduction of pYSTAT1 in the
FE-PD cell line (Supplementary Fig. 6d).
For determination of ADCT-301 efficacy in vivo, we
subcutaneously xenotransplanted three ALCL, ALK− cell lines,
Mac-2A, TLBR-1 and FE-PD, into NOD-scid Il2rgnull (NSG) mice
and intravenously administered a single dose (0.5 mg/kg) of
ADCT-301, control ADC B12-SG3249, or vehicle (PBS) when
tumors reached 100–150mm3. This single dose of ADCT-301
completely prevented growth of Mac-2A and TLBR-1 tumors and
led to tumor growth retardation of rapidly growing FE-PD cells
(Fig. 4d and Supplementary Fig. 6e). The control ADC did not
elicit any anti-tumor activity. This remarkable tumor control of
ADCT-301 confirmed the high efficacy of IL-2Rα-mediated
targeting of ALCL cell growth.
Discussion
ALCL is a heterogeneous disease comprised of systemic ALCL,
ALK+ and ALK−, pcALCL and BIA-ALCL. Whereas the prog-
nosis of adult ALCL, ALK+ and subgroups of ALCL, ALK− is
usually good, relapses occur frequently in pediatric ALCL, ALK+,
and the outcomes of patients with relapsed/refractory ALCL
patients and advanced BIA-ALCL are rather poor, highlighting an
unmet medical need for these patients2,7.
Ideally, therapeutic targets are not only specific to the respec-
tive tumor cells, but, at the same time, are essential components
of growth and survival pathways. Screening for SEs is a valuable
tool for identification of such genes21,22,24. In our SE analyses, the
identification of known ALCL-promoting genes, such as JUNB,
IRF4, STAT1, STAT3 and CD308,9,25,26,41, validated our approach
and independently confirmed previous findings on the patho-
genic role of JUNB, IRF4 and STAT transcription factors in
ALCL. Of note, BATF3, IRF4 and STAT3 are present in the top-
ten “preferentially essential genes” in ALCL, ALK+ cell lines
identified by CRISPR screen analyses within the Achilles project
(depmap.org; Supplementary Fig. 6f)42. Furthermore, BATF-
family and IRF4 genes are involved in chromosomal transloca-
tions in ALCL, supporting their biological relevance29,43.
Remarkably, both the AP-1-family member BATF3 and IL-
2R components were consistently found among the top SE-
associated genes in ALCL cell lines and primary ALCL samples,
which attracted our attention for detailed analyses given our
previous findings on AP-1/BATF function in ALCL and the
important role of IL-2/IL-2R for T lymphocyte growth and
function12,18. We further extend the ALCL pathogenic concept
on IL-2/IL-15/IL-2R-components and define the BATF3/IL-2R
module as a central component for ALCL growth and survival
(Fig. 4e). Furthermore, despite harboring JAK2 or STAT3
mutations44, ALCL, ALK− cell lines strongly responded to IL-2,
underscoring its growth-supportive role in ALCL. IL-2Rγ was
described to be suppressed by NPM1-ALK20. However,
according to our data (Fig. 1h), IL-2Rγ-silencing rarely occurs
in ALCL. Regarding IL-2, its lack of expression in ALCL cells
itself may be explained by their strong IL-10 expression, which
can actively suppress IL-2 production in T cells45. However,
cells in the ALCL tumor microenvironment can be assumed to
produce IL-234,35, and in the majority of cases, ALCL cells
produce IL-15, both accounting for IL-2R stimulation in
primary ALCL.
Our data suggest that high-level IL-2Rα expression might be
associated with a more aggressive clinical presentation in two
independent ALCL cohorts, which has to be confirmed in larger
ALCL cohorts. However, this finding reflects our functional stu-
dies and is in line with the correlation of high soluble IL-2Rα
levels with more aggressive disease and lower EFS at 3 years in
ALCL, ALK+ children cohorts35. As risk factor, IL-2Rα expres-
sion might be outcompeted by more intense treatment regimens
with brentuximab-vedotin (BV)-containing regimens or SCT in
our adult ALCL, ALK− cohort. Moreover, it is unlikely that
DUSP22 and TP63 rearrangements, having been described in
ALCL, ALK−43,46, are confounding factors in our survival ana-
lysis based on the following findings. In the first clinical report,
the 5-year OS of 21 patients with DUSP22 rearrangement was
90%7. However, in a later work from the British Columbia Cancer
Lymphoid Cancer database, the 5-year OS of 12 patients with
DUSP22 rearrangement was 40%47. Thus, the prognostic impact
of DUSP22 rearrangement is currently unclear, and it may be
more related to prognostic factors such as IPI. In addition, in
pcALCL, no impact of DUSP22 rearrangement (present in about
30% of cases) on prognosis was observed48. Despite that TP63
rearrangement has a confirmed poor prognosis in ALCL, ALK−,
it is indeed very rare. We also revealed a BATF3-dependency of
Fig. 3 IL-2 and IL-15 promote ALCL proliferation and activate STAT1, STAT5 and ERK1/2. a Indicated 7 ALCL cell lines were treated with rhIL-2 (100 ng/
ml). Control cell lines were SUP-M2 (ALK+, IL-2Rγ-negative) and Jurkat (T-cell leukemia-derived, IL-2Rα- and IL-2Rβ-negative). Resazurine assay was used
to measure metabolic activity as a marker of cell proliferation. Data are means ± SD of biological triplicates given as a percentage of the untreated control. P
values were determined by two-tailed unpaired Student’s t test; n.s. not significant. Structure of IL-2 bound to the trimeric IL-2R complex is shown (PDB ID:
2B5I). b In BATF3-KO cells, no IL-2-induced proliferation in Karpas-299 (ALK+) and Mac-1 (ALK−) could be seen compared to CRISPR control. Proliferation
was determined by resazurine assay. Data are normalized to untreated control and shown as means ± SD of biological triplicates. P values were determined
by two-tailed unpaired Student’s t test. c Immunoblot analysis of total STAT1, STAT5 and ERK1/2 proteins and their phosphorylated (pY, pT/Y) forms in
Mac-2A (ALK−), TLBR-2 (BIA) and Jurkat control cells stimulated with rhIL-2 (50 or 100 ng/ml), Neo-2/15 (100 ng/ml) or PBS (−) as control. GAPDH
serves as loading control. Blots shown are representative of two independent experiments with similar results in different cell lines. d Limiting dilution of
Karpas-299 (ALK+), Mac-1 (ALK−) and Jurkat control cells with or without rhIL-2 (100 ng/ml) in a 96-well plate containing RPMI1640 and 10% FCS. At
day 0, the indicated number of cells were seeded and incubated for 2 weeks. Representative example of biological triplicates is shown. e Inhibition of IL-2-
induced proliferation by the IL-2Rα-blocking antibody Basiliximab (1 μg/ml). Proliferation was determined by resazurine assay. Data are normalized to
control-treated cells and shown as means ± SD of biological triplicates. P values were determined by two-tailed unpaired Student’s t test. f Representative
images of 9 patient samples measured of IL-15 IHC staining in fresh-frozen primary ALCL tissue. g Effect of IL-15 (50 ng/ml) on cell proliferation of
indicated 4 ALCL and Jurkat cell lines. SU-DHL-1 (ALK+, IL-2Rγ-negative) and Jurkat (T-cell leukemia-derived, IL-15Rα- and IL-2Rβ-negative) serve as
control cell lines. Proliferation was measured by [3H]-thymidine incorporation. Values represent means ± SD of biological triplicates as percentage of
untreated control. P values were determined by two-tailed unpaired Student’s t test; n.s. not significant. h Immunoblot analysis of STAT1, STAT5 and ERK1/
2 proteins and their phosphorylated (pY, pT/Y) forms in FE-PD (ALK−) and Jurkat control cell lines stimulated with rhIL-15 (50 or 100 ng/ml), Neo-2/15
(100 ng/ml) or PBS (−) as control. GAPDH protein expression serves as control.
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the ALCL hallmark-gene CD30. Whether IL-2R and CD30
are interconnected and IL-2R-signaling substitutes for the
loss of TCR-signaling in ALCL15,16 has to be determined in
future studies.
Given the unsatisfactory treatment response of particular
subgroups of systemic ALCL, ALK− patients, relapsed/refractory
systemic ALCL patients or relapsed pediatric ALCL, ALK+
patients to standard chemotherapy, there is a medical need for
Fig. 4 IL-2Rα expression in ALCL patients correlates with survival and represents potential therapeutic target. a OS of pediatric ALCL, ALK+ patients
(NHL-BFM cohort, n= 88), and b EFS and OS of adult ALCL, ALK− patients without SCT (n= 34) having low (staining intensity, SI= 0–2) or high (SI= 3)
IL-2Rα expression. Kaplan–Meier curves of individual groups were compared using two-tailed log-rank statistics. c Indicated 9 ALCL cell lines and 2 T-cell
leukemia-derived control cell lines were incubated for 96 h with different concentrations of PDB dimer linked antibodies targeting either IL-2Rα
(ADCT-301) or, as a non-binding control, the glycoprotein gp120 of HIV (B12-SG3249) to determine the LD50. Means ± SD of biological triplicates are
shown. d In vivo anti-tumor efficacy of ADCT-301 in murine xenograft models of Mac-2A (ALK−) or TLBR-1 (BIA) ALCL cell lines. For each cell line, mice
were randomized into three groups to receive a single dose of either vehicle (PBS, n= 4), control ADC (B12-SG3249, 0.5 mg/kg, n= 5), or ADCT-301
(0.5 mg/kg, n= 5) intravenously at day 1 (indicated by an arrow). Tumor volumes were measured with caliper over time and are shown as means ± SEM.
P values were determined by two-tailed unpaired Student’s t test. e Schematic illustration of the proposed mechanism.
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new effective treatment strategies49. With implementation of
chemotherapy regimens containing BV, which proved to be the
first effective targeted treatment for ALCL in many years4, in
frontline ALCL therapy, effective treatment options remain
lacking in the second line. For ALCL, ALK+ patients, pharma-
cological ALK-inhibition might be a treatment option in this
setting50,51. IL-2Rα has been investigated as immunotherapeutic
tool for other malignancies52,53. ADCT-301, which has entered
clinical trials (e.g., ClinicalTrials.gov Identifier: NCT02432235
and NCT04052997), killed ALCL cells with high efficacy39.
Notably, ADCT-301-coupled PBD dimers, given their unique
mode of action, are likely to overcome resistance to conventional
chemotherapy54. Interestingly, ADCT-301 treatment in pre-
clinical models and in patients with advanced solid tumors or
lymphomas resulted in transient reduction of Treg cells, while
CD4+ and CD8+ T cells were unaffected, which might enhance
ADCT-301-mediated anti-tumor activity55–57. Together, by our
unbiased approach we identify the BATF3/IL-2R-module as
vulnerability in ALCL, and our data strongly argue for explora-
tion of IL-2Rα-targeting of ALCL in clinical trials.
Methods
Cell lines and cell culture. ALCL (Karpas-299, SU-DHL-1, DEL, JB6, SR-786
and SUP-M2, all ALK+; FE-PD, Mac-1, Mac-2A and DL-40, all ALK−), T-cell
leukemia-derived (Jurkat, KE-37, Molt-14 and H9) and HEK293T cell lines were
cultured as described9,28. If not stated otherwise, ALCL cell lines were obtained
from the ATCC cell line repository. Non-ALCL T-cell leukemia-derived cell
lines were received from the DSMZ collection (Braunschweig, Germany). Cell
lines are regularly tested for mycoplasma contamination, and cell line identity
has been verified by STR DNA fingerprinting (R. Siebert, Ulm, Germany). BIA-
ALCL (TLBR-1, TLBR-2 and TLBR-3) cell lines were kindly provided by Alan
Epstein (California, USA) and cultured in RPMI 1640 supplemented with 10%
FBS, 100 IU/ml penicillin, 50 mg/ml streptomycin sulfate and 330 ng/ml in-
house synthesized IL-2-Fc. FE-PD cell line was kindly provided by Annarosa
del Mistro as a gift (Veneto Onocology Insitute Padua, Italy). Mac-1 and Mac-
2A cell lines were kindly provided by Marshall E. Kadin as a gift (Harvard
Medical School, Boston, MA). DL-40 was kindly provided by Masanori Daibata
(Kochi, Japan).
Cell numbers were determined using a CASY Cell Counter. For cytokine
stimulation, monoclonal antibody and ADC treatment, rhIL-2 (50 or 100 ng/ml;
1081-IL, R&D Systems), rhIL-15 (50 or 100 ng/ml; 247-ILB, R&D Systems), Neo-2/
1536 (100 nglml), basiliximab (1 μg/ml; ab00188, Absolute Antibody) and ADCT-
301 (in vitro: 156 ng/ml, in vivo: 0.5 mg/kg; camidanlumab tesirine, ADC
Therapeutics) were applied as indicated.
Human samples. All human samples were obtained with informed written consent
and in accordance with the Declaration of Helsinki reviewed by the local ethic
boards (Medical University of Vienna 1221/2019; University Hospital Brno 4-306/
13/1). FFPE tissues from systemic ALCL, ALK− cases collected through
TENOMIC, a transnational research consortium on T-cell lymphomas involving
several centers in France, Belgium and Switzerland, were used for immunohisto-
chemical validation. The TENOMIC database is approved by the ethical committee
“CPP Ile-de-France IX 08-009”.
Genome-wide occupancy analysis. ChIP-seq was performed as described58,59.
Primary antibodies used for analysis are listed in Supplementary Table 7. In short,
for each ChIP, 5 μg of antibody was conjugated to 2 mg of M-270 Epoxy Dyna-
beads (Thermo Fisher) and added to sonicated nuclear extract. Library construc-
tion was performed using the Swift 2S Turbo DNA library kit as per the
manufacturer’s instructions (Swift Biosciences). Illumina sequencing was per-
formed using the NextSeq500 platform with single-end 75 bp reads.
ChIP-seq processing and display. Reads were aligned to the human genome
(hg19) using bowtie with parameters –k 2 –m 2 –best and –l set to the read length.
For visualization, WIG files were created from aligned ChIP-seq read positions
using MACS with parameters –w –S –space=50 –nomodel –shiftsize=200 to
artificially extend reads to be 200 bp and to calculate their density in 50 bp bins.
Read counts in 50 bp bins were then normalized to the millions of mapped reads,
giving reads per million (rpm) values. WIG and TDF files were visualized in the
IGV 2.4.6 genome browser.
ChIP-seq enriched regions. Regions enriched in ChIP-seq signal were identified
using MACS with corresponding control and parameters –keep-dup=auto and –p
1e−9. The distribution of peaks into other genomic features was determined by
overlapping peaks with SEs, typical enhancers, promoters, and gene bodies, in this
order. SEs and typical enhancers from the same cell type as the TF ChIP-seq were
used. Promoters were defined as 4 kb windows centered on the transcription start
sites of RefSeq genes. Gene bodies were defined as the remaining portion of genes
longer than 2 kb from 2 kb downstream of the promoter to the transcription
end site.
SE identification and assignment. SEs were identified using ROSE (https://
bitbucket.org/young_computation/rose) algorithm with some modifications.
Reads overlapping ENCODE blacklist regions were removed using bedtools
intersect. From the remaining reads, two sets of peaks of H3K27ac were iden-
tified using MACS with parameter sets –keep-dup=auto –p 1e−9 and –keep-
dup=all –p 1e−9. H3K27ac peaks were stitched computationally if they were
within 12500 bp of each other, though peaks fully contained within+/− 2000bp
from a RefSeq promoter were excluded from stitching. These stitched enhancers
were ranked by their H3K27ac signal (length * density) with input signal sub-
tracted. SEs were defined geometrically as those enhancers above the point at
which the line y= x is tangent to the curve. Stitched enhancers (typical
enhancers and SEs) were assigned to the single active gene whose transcription
start site is nearest the center of the stitched enhancer. Active genes were
determined by taking the top two-thirds of all RefSeq promoters (+/−500 bp)
ranked by their H3K27ac signal. H3K27ac signal in promoters was determined
using bamToGFF (https://github.com/BradnerLab/pipeline) with parameters –e
200 –m 1 –r –d.
RNA-seq and bioinformatic analysis. RNA isolation was performed using the
RNeasy Mini Kit (Qiagen) and RNA quality was assessed on a Fragment Analyzer
(Advanced Analytical Technologies)− SS Total RNA 15nt. RNA-seq libraries were
prepared using the NEBNext Ultra II Directional RNA Library Prep Kit for Illu-
mina (New England Biolabs) with Poly(A) selection according to the manu-
facturer’s instructions. Library quantification was examined on a Fragment
Analyzer−HS NGS Fragment 1-6000 bp and Qubit HS dsDNA Kit (Invitrogen).
Libraries were pooled and sequenced to 75 bp single-end on the Illumina NextSeq
500 platform. Sequencing data were analyzed as described60.
CRISPR/Cas9 genome editing. Cloning of gRNA lentiCRISPR v2 plasmid, len-
tiviral packaging, lentiviral transduction and single clone isolation were performed
as described12. The lentiviral Cas9-containing plasmid lentiCRISPR v261 was a gift
from F. Zhang (Addgene #52961, Cambridge, USA). Non-targeting and BATF3
gRNAs were designed using the E-CRISP program, version 5.4 (www.e-crisp.org/E-
CRISP/index.html), which targeting the first exon of BATF3. Sequences of gRNA
oligonucleotides are listed in Supplementary Table 8.
Immunostaining and quantification. IHC was performed on FFPE (formalin-
fixed paraffin embedded) sections with the conventional avidin–biotin–peroxidase
method. Heat antigen retrieval was performed using citrate buffer pH 6.1 (Agilent
Dako). Endogenous peroxidases were quenched by incubating sections in 3% H2O2
in PBS. Sections were blocked using Avidin/Biotin Blocking Kit (Vector Labora-
tories). Primary antibodies were added in 1% BSA/PBS at 4 °C overnight. Slides
were incubated with biotin-conjugated secondary antibodies using IDtect Super
Stain System—HRP (Empire Genomics) and developed using AEC Substrate Kit
(BDPharmingen). Slides were mounted with Aquatex (Merck). Primary antibodies
used are listed in Supplementary Table 7 and dilutions used are as follows: CD30
(1:50), IL-2 (1:200), IL-2Rα (1:50), IL-2Rβ (1:40), IL-2Rγ (1:20), BATF3 (100 μg/
ml), IL-15 (10 μg/ml) and IL-15Rα (7 μg/ml). Stained slides were further assessed
by two experienced pathologists who were blinded to the clinicopathological
parameters and patient outcome. Quantification of the slides was determined using
the histoscore system. Stained slides were scored for both the intensity and per-
centage of positively staining cells: 0 negative, 1+ weak, 2+ moderate and 3+
strong staining. Positive staining was considered if present in >1% of cells. The
Histoscore was then calculated by multiplying the intensity by the percentage of
positively stained cells.
End-point and quantitative RT-PCR. RNA preparation, cDNA synthesis, semi-
quantitative and quantitative PCR analyses were performed as described9. Primers
are listed in Supplementary Table 8.
Flow cytometry. Surface protein expression of IL-2Rα, IL-2Rβ, IL-2Rγ, CD30 and
IL-15Rα on ALCL and T-cell leukemia-derived cell lines was determined by flow
cytometry. Primary (all 1:50) and corresponding isotype control (all 1:50) anti-
bodies are listed in Supplementary Table 7. Apoptotic cell death was determined by
Annexin V/PI staining according to the manufacturer’s instructions (Bender
MedSystems). Data were acquired with a BD FACSCanto II and analyzed with
FACSDiva software 8.0.1 (Becton Dickinson).
EMSA. Nuclear protein preparation and EMSA were performed as described9. AP-
1 motifs of the respective IL2R promoter (IL2RA) or enhancer (IL2RB) gene
regions were identified using LASAGNA-Search 2.0 online tool and EMSA probes
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were designed accordingly. EMSA oligonucleotides are listed in Supplementary
Table 8. Based on the experimental method, no molecular weight markers can be
shown for EMSA analyses.
ChIP and real-time PCR analyses. ChIP assays were performed in two biological
replicates using antibodies for BATF3 (AF7437, R&D Systems) according to a
modified Millipore protocol (http://www.merckmillipore.com/DE/de/product/
ChromatinImmunoprecipitation%28ChIP%29-Array-Kit,MM_NF-17-
295#anchor_BRO) as described12. In short, cells were fixed using the two-step
cross-linking method (2 mM disuccinimidyl glutarate for 30 min followed by 1%
formaldehyde for 5 min) and lyzed with 50 mM Tris-HCl, pH 8.0/5 mM EDTA/1%
SDS. Thereafter, samples were sonicated with the Bioruptor Plus (Diagenode; 13
cycles, intensity High, sonication 30 s/break 30 s per cycle). Chromatin was pre-
cleared with bovine serum albumin (BSA)-saturated Protein A-Sepharose and
incubated overnight at 4 °C with BATF3 antibody (27 μg/1 × 107 cells). Immuno-
complexes were collected with BSA-saturated Protein A-Sepharose for 1 h at 4 °C.
After washing, protein-DNA complexes were eluted using 1% SDS/0.1 M NaHCO3.
Reversal of the cross-linking, RNAse treatment, proteinase K digestion, and DNA
purification by phenol-chloroform extraction were performed according to stan-
dard protocols. Primary antibody and primer sequences are shown in Supple-
mentary Table 7 and Table 8, respectively. Quantitative PCR was carried out in
technical triplicates with ChIP-DNA isolated from to 3 × 105 cell equivalents using
the CFX96 system and GoTaq qPCR Master Mix (Promega). Non-recruiting
intergenic regions on chromosomes 4 (Ref_Ch4) were amplified as references. A
total of 4 ng input DNA was used as a control.
Cell proliferation assay. Cells were starved in medium with 1% FCS overnight
and seeded in 96-well plates with 2 × 104 cells per well. Cell proliferation was
measured after 72 h of cytokine stimulation with or without monoclonal antibody
treatment by resazurin assay or [3H]-thymidine incorporation according to man-
ufacturer’s instructions. All values were normalized to the control-treated cells.
Immunoblotting. Whole protein lysate preparation and immunoblot analyses were
performed as described28. Primary antibodies used are listed in Supplementary
Table 7 and dilutions used are as follows: BATF3 (1 μg/ml), STAT1 (1:1000),
pSTAT1 (Y701) (1:1000), STAT3 (1:1000), pSTAT3 (Y705) (1:1000), STAT5
(1:1000), pSTAT5 (Y694) (1:1000), ERK1/2 (1:1000), pERK1/2 (T202/Y204)
(1:1000), PARP1 (1:1000), β-ACTIN (1:1000), β-TUBULIN (1:1000) and GAPDH
(1:10000).
Murine xenograft model. Both male and female NSG mice were purchased from
the National Cancer Institute (Frederick, MD). ALCL cells (1 × 106; FE-PD, Mac-2A
or TLBR-1) were subcutaneously implanted into the hind flanks of nine- to ten-week
old mice. When tumor volumes reached ~100–150mm3, mice were randomly allo-
cated into three groups to receive vehicle (PBS), non-binding ADC (B12-SG3249) or
ADCT-301 (camidanlumab tesirine) (both ADC Therapeutics, 0.5 mg/kg, intravenous
injection). Tumors were measured with caliper every three days. Tumor size was
estimated using the following formula: volume (mm3)= (length × width2)/2. Each
mouse was euthanized when its tumor reached the end-point volume of 2000mm3 or
at the study end. Animal work was carried out according to an ethical animal license
protocol that was approved by the Medical University of Vienna and Austrian
Ministry of Education and Science (BMBWF-66.009/0200-V/3b/2018 and Addendum
Zl. 18/115-97/98, 2019).
Statistical analysis. Statistical analyses were performed using GraphPad Prism
v6.0 and R v4.0.3 software. Data of protein expression in TMAs are presented in
box-and-whisker plots with indication of medians, quartiles and ranges, each data
point represents an individual score. Correlation of data was determined by the
Pearson correlation coefficient. Other data are presented as means ± SD or SEM as
stated in the respective figure legends. Differences between mean values of two
groups were evaluated by the two-tailed unpaired Student’s t test. Estimation of
EFS and OS was performed using the Kaplan–Meier method using IBM SPSS
Statistics Version 22 with the survival package of R (v3.2-7; Therneau, 2020).
Events were defined as relapse, progressive disease or death from any cause. Dif-
ferences between groups were compared by a log-rank test. P values < 0.05 were
considered to be statistically significant.
Reporting summary. Further information on research design is available in the Nature
Research Reporting Summary linked to this article.
Data availability
All RNA-seq and ChIP-seq datasets produced in this study are deposited in Gene
Expression Omnibus (GEO) under SuperSeries GSE158916. Source data is provided for
the Fig. 1a–d, Supplementary Fig. 1 and Supplementary Fig. 2a–d. The Crescenzo et al.29
and Iqbal et al.30 publicly available data used in this study are available in the Sequence
Read Archive (SRA) and GEO database under accession code SRP044708 and GSE19069,
respectively. ChIP-seq of H3K27ac and input DNA of normal T-cell subsets and Jurkat
cell line used in this study are publicly available in GEO under the accession numbers
GSM1058764, GSM1058789, GSM772835, GSM772916, GSM1102781, GSM1102806,
GSM1296384 and GSM569086. The remaining data are available within the Article,
Supplementary Information or Source Data file. Source data are provided with this paper.
Code availability
Computer code used in this study is available within Supplementary Software.
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